论文部分内容阅读
目的:评价参附注射液对晚期前列腺癌患者血清前列腺特异抗原(Prostate Specific Antigen,PSA)水平及生存质量的影响。方法:60例前列腺癌患者,分成观察组和对照组。对照组:给予常规治疗。观察组:在常规治疗的基础上,加用参附注射液治疗。结果:治疗后,两组前列腺癌患者的身体状况、功能状况等评分均有显著改善,差异具有统计学意义(P<0.05);治疗后,观察组前列腺癌患者的身体状况、功能状况等评分均优于对照组,差异具有统计学意义(P<0.05)。治疗后,两组前列腺癌患者血清PSA水平均有显著改善,差异具有统计学意义(P<0.01);治疗后,观察组前列腺癌患者血清PSA水平低于对照组,差异具有统计学意义(P<0.01)。结论:参附注射液治疗晚期前列腺癌患者具有较佳疗效,能有效改善患者的血清PSA水平及生存质量。
Objective: To evaluate the effect of Shenfu injection on serum PSA and quality of life in patients with advanced prostate cancer. Methods: Sixty patients with prostate cancer were divided into observation group and control group. Control group: given conventional treatment. Observation group: On the basis of routine treatment, add Shenfu injection. Results: After treatment, the scores of physical status and functional status of two groups of patients with prostate cancer were significantly improved (P <0.05). After treatment, the scores of physical status and functional status of patients with prostate cancer in the observation group All were better than the control group, the difference was statistically significant (P <0.05). After treatment, the serum PSA levels of two groups of patients with prostate cancer were significantly improved, the difference was statistically significant (P <0.01); after treatment, the serum PSA level of prostate cancer patients in the observation group was lower than that of the control group, the difference was statistically significant (P <0.01). Conclusion: Shenfu injection in patients with advanced prostate cancer has better curative effect, which can effectively improve the serum PSA level and quality of life in patients.